Compare Align Technology, Inc. (ALGN) vs Xylem, Inc. (XYL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Align Technology, Inc. vs Xylem, Inc. — how do they compare? Align Technology, Inc. trades at $179.45 (market cap $12.86B), while Xylem, Inc. trades at $121.23 (market cap $28.81B). The key difference: Xylem, Inc. is far larger — about 2.2× Align Technology, Inc.'s market cap, and Xylem, Inc. pays a 1.42% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.
| ALGN | XYL | |
|---|---|---|
Market Cap | $12.86B | $28.81B |
Sector | Health | Industrials |
52-Week High | $207.19 | $152.95 |
52-Week Low | $124.88 | $106.34 |
Enterprise Value | $11.92B | $30.07B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
XYL trades at $121.22, up 1.96% with a bullish technical outlook. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.12 exceeding expectations. Revenue grew to $9.04B in 2025, and net income margin improved to 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing growth in water technology solutions. The company maintains a strong balance sheet with total assets of $16.49B and shareholder equity of $10.64B as of 2024.
XYL presents a favorable investment case with analyst consensus price target of $153.14, implying 26% upside. Strengths include steady revenue growth, expanding margins, and positive cash flow trends. Risks involve market volatility and execution challenges in scaling new partnerships. Institutional sentiment is mixed but leans bullish, supported by a 47.5% buy rating from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
